<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="546">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05154045</url>
  </required_header>
  <id_info>
    <org_study_id>BL61</org_study_id>
    <nct_id>NCT05154045</nct_id>
  </id_info>
  <brief_title>Diabetes-Specific Formula and Glycemic Control in Individuals With Type 2 Diabetes</brief_title>
  <official_title>Effect of Diabetes-Specific Formula and Oatmeal on Glycemic Control in Individuals With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Nutrition</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Nutrition</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled, crossover study to compare the effects of two treatments on&#xD;
      postprandial glucose in adults with type 2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose positive area under the curve (AUC)</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Calculated from blood samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin positive area under the curve (AUC)</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Calculated from blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin peak value</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Calculated from blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose peak value</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Calculated from blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin peak time</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Calculated from blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose peak time</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Calculated from blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Concentrations</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Calculated from blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose Concentrations</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Calculated from blood samples</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Glucagon-Like Peptide-1 (GLP-1) positive area under the curve (AUC)</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Calculated from blood samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucagon-Like Peptide-1 (GLP-1) peak value</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Calculated from blood samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucagon-Like Peptide-1 (GLP-1) peak time</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Calculated from blood samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Glucagon-Like Peptide-1 (GLP-1) Concentrations</measure>
    <time_frame>0 to 240 minutes</time_frame>
    <description>Calculated from blood samples</description>
  </other_outcome>
  <other_outcome>
    <measure>Appetite Questionnaire</measure>
    <time_frame>Study Day 1 to Study Day 7</time_frame>
    <description>5 Visual analog scales; Including Score from Not at All to Extremely or Nothing to Most</description>
  </other_outcome>
  <other_outcome>
    <measure>Sensory Questionnaire</measure>
    <time_frame>Study Day 1 to Study Day 7</time_frame>
    <description>10 sensory and hedonic questions; Up to 9-Point Likert Scale questions including Dislike Extremely to Like Extremely or Much too to Much less or Not at all to Extremely</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Glycemic Control</condition>
  <arm_group>
    <arm_group_label>Experimental Formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One 330 ml serving of study product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Test Meal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 g Instant oatmeal</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Experimental Formula</intervention_name>
    <description>Diabetes-specific study formula</description>
    <arm_group_label>Experimental Formula</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Test Meal</intervention_name>
    <description>Instant oatmeal</description>
    <arm_group_label>Test Meal</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 21 and ≤ 65 years.&#xD;
&#xD;
          -  Participant has type 2 diabetes as evidenced by use of oral antihyperglycemic&#xD;
             medication(s) with constant dose for at least two months prior to screening and&#xD;
             baseline visit and has been diagnosed with type 2 diabetes within the past 10 years.&#xD;
             Participant is able to maintain medication number, type and dose throughout the&#xD;
             duration of study.&#xD;
&#xD;
          -  Participant with a BMI &gt; 18.5 and ≤ 35.0 kg/m2&#xD;
&#xD;
          -  Participant is weight stable for the two months prior to the screening visit.&#xD;
&#xD;
          -  Male or a non-pregnant, non-lactating female, at least 6 weeks postpartum prior to&#xD;
             screening visit.&#xD;
&#xD;
          -  If the participant is on a chronic medication such as an anti-hypertensive,&#xD;
             lipid-lowering, thyroid medication or hormone therapy, the dosage must be constant for&#xD;
             at least two months prior to screening and baseline visit. Participant is able to&#xD;
             maintain medication number, type and dose throughout the duration of study.&#xD;
&#xD;
          -  Participant is willing to follow protocol as described, including consumption of study&#xD;
             product per protocol and completing any forms needed throughout the study.&#xD;
&#xD;
          -  Participant has at least a two-week washout period between completion of a previous&#xD;
             research study that required ingestion of any study food or drug and Visit 2 when&#xD;
             assigned study product is consumed.&#xD;
&#xD;
          -  Participant is willing to refrain from taking non-study diabetes-specific formulas&#xD;
             over the entire course of the study.&#xD;
&#xD;
          -  Participant has voluntarily signed and dated an Informed Consent Form (ICF), approved&#xD;
             by an Independent Ethics Committee/Institutional Review Board (IEC/IRB) prior to any&#xD;
             participation in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has a screening HbA1c level &lt; 7% or ≥ 10%.&#xD;
&#xD;
          -  Participant uses exogenous insulin or GLP-1 agonists or DPP-4 inhibitors for glucose&#xD;
             control.&#xD;
&#xD;
          -  Participant has confirmed type 1 diabetes and/or had history of diabetic ketoacidosis.&#xD;
&#xD;
          -  Participant has current infection, inpatient surgery or received systemic&#xD;
             corticosteroid treatment in the last 3 months; or received antibiotics in the last 3&#xD;
             weeks.&#xD;
&#xD;
          -  Participant has active malignancy.&#xD;
&#xD;
          -  Participant has significant cardiovascular event within 6 months prior to study entry&#xD;
             or history of congestive heart failure.&#xD;
&#xD;
          -  Participant has end stage organ failure or was post organ transplant.&#xD;
&#xD;
          -  Participant has a history of renal disease or severe gastroparesis.&#xD;
&#xD;
          -  Participant has current hepatic disease.&#xD;
&#xD;
          -  Participant has had bariatric surgery including gastric balloon; history of&#xD;
             gastrointestinal disease or intestinal surgery that can interfere with consumption or&#xD;
             digestion or absorption of study product.&#xD;
&#xD;
          -  Participant has a chronic, contagious, infectious disease, such as active&#xD;
             tuberculosis, Hepatitis A, B or C, or HIV.&#xD;
&#xD;
          -  Participant has eating disorder, severe dementia or delirium, history of significant&#xD;
             neurological or psychiatric disorder, alcoholism, substance abuse or other conditions&#xD;
             that may interfere with study product consumption or compliance with study protocol&#xD;
             procedures.&#xD;
&#xD;
          -  Participant is taking any herbals, dietary supplements, or medications, other than&#xD;
             allowed anti-hyperglycemic medications, during the past four weeks prior to screening&#xD;
             visit that could profoundly affect blood glucose or appetite.&#xD;
&#xD;
          -  Participant uses diabetes-specific formula(s), defined as more than one eating&#xD;
             occasion per week in the last three months.&#xD;
&#xD;
          -  Participant has clotting or bleeding disorders. The use of Plavix® or a similar&#xD;
             anticoagulant drug with no reported difficulty during blood draws is allowed and&#xD;
             participant is able to maintain medication number, type and dose throughout the&#xD;
             duration of study.&#xD;
&#xD;
          -  Participant participates in another study that has not been approved as a concomitant&#xD;
             study by AN.&#xD;
&#xD;
          -  Participant has an allergy or intolerance to any ingredient in the study product, as&#xD;
             reported by the participant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sara Thomas, PhD, RDN</last_name>
    <role>Study Chair</role>
    <affiliation>Abbott Nutrition</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kristen DeLuca, MS, RDN, LDN</last_name>
    <phone>614-624-5455</phone>
    <email>kristen.deluca@abbott.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials, LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>December 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

